Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia. Kugler E, Cohen I, Amitai I, Ram R, et al. Br J Haematol 2024;205:932-941.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kugler E, Cohen I, Amitai I, Ram R, et al. Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia. Br J Haematol 2024;205:932-941.
PMID: 38782575